Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

Pérez Alba, Eduardo y Nuzzolo Shihadeh, Laura Marina y Aguirre García, Gloria Mayela y Espinosa Mora, Jaime Eugenio y Lecona García, Juan Diego y Flores Pérez, Romulo Omar y Mendoza Garza, Marisela y Camacho Ortiz, Adrián (2021) Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. Journal of Microbiology, Immunology and Infection, 54 (5). pp. 787-793. ISSN 16841182

[img]
Vista previa
Texto
22454.pdf - Versión Publicada
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (542kB) | Vista previa

Resumen

Objective: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Methodology: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) thatwere treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates. Results: A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD � 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/ 197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P Z <.05). There was no difference in hospital acquired infections between both groups.

Tipo de elemento: Article
Palabras claves no controlados: COVID-19, SARS-CoV-2, Baricitinib, Dexamethasone.
Materias: Q Ciencia > QR Microbiología
R Medicina > RC Medicina Interna, Psiquiatría, Neurología
Divisiones: Medicina
Usuario depositante: Editor Repositorio
Creadores:
CreadorEmailORCID
Pérez Alba, EduardoNO ESPECIFICADONO ESPECIFICADO
Nuzzolo Shihadeh, Laura MarinaNO ESPECIFICADONO ESPECIFICADO
Aguirre García, Gloria Mayelagloria.m.aguirre@gmail.comNO ESPECIFICADO
Espinosa Mora, Jaime Eugeniodr.jaime.espinosa88@gmail.comNO ESPECIFICADO
Lecona García, Juan DiegoNO ESPECIFICADONO ESPECIFICADO
Flores Pérez, Romulo OmarNO ESPECIFICADONO ESPECIFICADO
Mendoza Garza, MariselaNO ESPECIFICADONO ESPECIFICADO
Camacho Ortiz, AdriánNO ESPECIFICADONO ESPECIFICADO
Fecha del depósito: 11 Nov 2021 21:39
Última modificación: 11 Nov 2021 21:54
URI: http://eprints.uanl.mx/id/eprint/22454

Actions (login required)

Ver elemento Ver elemento

Downloads

Downloads per month over past year